Credit Acceptance

Showing 464 articles
Business

H&R Block: The Bull Case for a Tax Season Titan

Amid market volatility, H&R Block (HRB) presents a compelling value proposition. With aggressive share buybacks, robust cash flow, and strategic expansion beyond tax season, the financial services firm is drawing investor attention for its resilience and shareholder returns.

Business

Gilead Sciences Bets on Precision Oncology to Power Next Growth Phase

Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.

Business

DaVita Navigates Headwinds as Integrated Kidney Care Turns Profitable Ahead of Schedule

DaVita Inc. reported Q4 2025 results in line with expectations, highlighting a milestone first profitable year for its Integrated Kidney Care unit. While revenue per treatment accelerated, the company continues to face pressure from elevated patient mortality and rising benefit costs. Executives provided 2026 guidance projecting mid-single-digit operating income growth and a sharp rise in EPS, buoyed by share buybacks and the stabilization of prior investment losses.

Business

Simon Property Group Caps Strong Year with Strategic Acquisitions and Record Returns, Outlines Aggressive 2026 Growth Plan

Simon Property Group reported robust fourth-quarter and full-year 2025 results, highlighted by record funds from operations, $2 billion in strategic acquisitions, and a significant return of capital to shareholders. The retail REIT giant provided optimistic 2026 guidance, banking on a strong development pipeline and resilient tenant demand despite acknowledging tariff-related headwinds.